Potential Alzheimer’s Treatments in Growing Number of Phase 2 and Phase 3 Studies, Group Reports

Potential Alzheimer’s Treatments in Growing Number of Phase 2 and Phase 3 Studies, Group Reports
The number of clinical trials evaluating possible treatments for Alzheimer’s disease is on the increase, according to a recent analysis conducted by ResearchersAgainstAlzheimer’s (RA2), a global network of Alzheimer’s researchers that is part of a non-profit organization promoting the study and treatment of this disease, called UsAgainstAlzheimer’s. The results were recently presented at this year’s UsAgainstAlzheimer’s National Alzheimer’s Summit, held in Washington’s, D.C., under the title “Where are We on the Path to 2025.” To date, there are 57 Phase 2 and 23 Phase 3 ongoing clinical trials to test potential Alzheimer’s medications, and 19 such drugs are estimated to come onto the market in the next five years. The analysis not only showed that the science behind Alzheimer’s is moving forward, but also that clinical trials are keeping up with drug development and research investigating new ways to combat the disease. “I am encouraged to see such a range of approaches to treating Alzheimer’s in Phase II development,” David Morgan, CEO of the University of South Florida’s Health Byrd Alzheimer’s Institute, said in a news release. “There is much work that still needs to be done, but the drugs in Phase II clinical trials offer a great deal of hope for the future.” Alzheimer’s dise
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *